The World Health Organization declared an end to COVID-19 as a public health emergency in May, but it warned at the time that the virus was still causing deaths and still mutating, and the emergence of the latest subvariants of the Omicron variant of SARS-CoV-2 has triggered new vaccine activity. The major producers of COVID-19 vaccines – Pfizer Inc./BioNTech SE, Moderna, Inc. and Novavax, Inc. – are gearing up to make their vaccines against the new subvariants available by the fall, after a long trend of falling vaccine sales.
The latest is Novavax, which said on 22 August that its 2023-2024 season COVID vaccine induced neutralizing responses to emerging subvariants EG.5.1, XBB.1.16.6, XBB.1.16, XBB.1.5 and XBB.2.3, and that the company was in the process of submitting for authorization from regulatory bodies around the world. The company had said in June that it was preparing multiple candidates to ensure its vaccine would be available in the fall, with the US Food and Drug Administration’s Center for Biologics Evaluation and Research working with it on manufacturing
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
